DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for bone development disease — screening already-approved drugs against its 27-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBone development disease maps to a 27-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedPazopanibApproved drug
Structures already discussed alongside bone development disease in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
fibroblast growth factor receptor 4 (FGFR4) — FGFR4 is one of the genes in this disease's Open Targets module — part of the target space DeCure's repurposing candidates point at. The protein backbone is drawn as a cartoon. The structure has 1-[4-[(1~{r})-1-[3,5-bis(chloranyl)pyridin-4-yl]ethoxy]-5-cyano-pyridin-2-yl]-3-[6-methanoyl-5-[(4-methyl-2-oxidanylidene-piperazin-1-yl)methyl]-3-(2-morpholin-4-ylethoxy)pyridin-2-yl]urea bound in it, shown as sticks.
Loading structure…
helix sheet 1~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8KH8 · 1.49 Å · ligand 1-[4-[(1~{R})-1-[3,5-bis(chloranyl)pyridin-4-yl]ethoxy]-5-cyano-pyridin-2-yl]-3-[6-methanoyl-5-[(4-methyl-2-oxidanylidene-piperazin-1-yl)methyl]-3-(2-morpholin-4-ylethoxy)pyridin-2-yl]urea (VVW). Experimental structure, not a prediction.
What the evidence adds up to
Mutations in three fibroblast-growth-factor receptor genes (FGFR1-3) have been identified as the cause of a variety of skeletal disorders, including achondroplasia, Apert syndrome, Crouzon syndrome, and Pfeiffer syndrome. The 2001 review notes that genomics approaches have yielded many genes involved in bone formation and remodelling, and that understanding these molecules may provide novel treatment strategies, but it does not report any clinical trial results.
A 2016 study developed a multilayered coating made of PLGA nanoparticles, heparin and chitosan to deliver dexamethasone and recombinant human bone morphogenetic protein-2 (rhBMP-2) locally. In vitro, the dual-drug coating upregulated alkaline phosphatase activity and osteo-related gene expression in C2C12 myoblasts. In vivo μCT and histological analysis showed that the dual-drug coating induced more ectopic bone formation than coatings loaded with either drug alone. The authors describe the system as a simple, safe and effective alternative to other DEX/rhBMP-2 delivery systems, but the study was limited to animal models and did not involve human patients with bone disease.
A 2025 systematic review of mesenchymal stem cell (MSC) transplantation for osteogenesis imperfecta included 9 human clinical studies (case reports or case series) covering 12 patients. Five studies reported an increase in total body bone mineral content, four observed a reduction in fracture rates after transplantation, and improvements in children's growth were recorded. Both bone-marrow-derived MSCs and human fetal MSCs appeared effective, but studies using bone-marrow-derived MSCs scored higher in methodological quality. The review explicitly calls for future randomised clinical trials with longer follow-up.
What remains missing are randomised controlled trials with adequate sample sizes and long-term follow-up for any of these approaches. For the FGFR mutation disorders, no drug therapy targeting the receptor mutations has been tested in patients in the abstracts provided. The dexamethasone/rhBMP-2 coating has not been tested in humans. The MSC transplantation evidence rests on 12 patients in uncontrolled case series. No trial has stratified patients by mutation type, disease severity, or age. Funding for definitive trials and standardised outcome measures are absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Trends in Genetics · 1995 · 297 citations · open access
Fibroblast-growth-factor receptor mutations in human skeletal disorders
AbstractFibroblast-growth-factor receptors (FGFRs), members of the tyrosine-kinase receptor family, play a crucial role in signal transduction and development. Recently, unique mutations in three human FGFR-encoding genes (FGFR1-3) have been identified as the cause of a variety of skeletal disorders. Comparison of these specific mutations with the resulting phenotypes is now providing new insight into the role of these receptors in normal and abnormal bone development.
American Journal of Health-System Pharmacy · 2006 · 54 citations
Cancer-treatment-induced bone loss, part 1
AbstractPURPOSE: The pathophysiology, frequency, sequelae, diagnosis, and treatment of cancer-treatment-induced bone loss (CTIBL) are discussed. SUMMARY: CTIBL is a long-term complication associated with cancer therapies that can directly or indirectly affect bone metabolism. Although CTIBL can occur in any patient receiving a cancer therapy known to cause bone loss, CTIBL is most common in patients with breast or prostate cancer who receive chemotherapy, hormone therapy, or surgical castration, as these can cause hypogonadism and induce bone loss. CTIBL causes bone fragility and an increased susceptibility to fractures; therefore, prevention, early diagnosis, and treatment of CTIBL are essential to decrease the risk of fracture. Bone loss occurs more rapidly and tends to be more severe in patients with CTIBL compared with those with normal age-related bone loss. Fractures of the hip, vertebra, and wrist are the fractures most commonly associated with bone loss. CTIBL is diagnosed by measuring bone mass using bone densitometry. Treatment of CTIBL consists of changing diet and lifestyle such as optimizing calcium and vitamin D intake, exercising, modifying behaviors known to increase the risk of CTIBL and pharmacologic therapy with hormone replacement therapy (HRT), selective estrogen-receptor modifiers (SERMs), calcitonin, or a bisphosphonate. CONCLUSION: Early identification and treatment of CTIBL are essential to prevent fractures. Patients should be instructed to optimize calcium and vitamin D intake, exercise regularly, and modify lifestyle behaviors known to cause bone loss. Patients with CTIBL should be treated with an oral or i.v. bisphosphonate; SERMs or HRT may be an option in some patients if contraindications do not exist.
Expert Opinion on Pharmacotherapy · 2013 · 53 citations
Pazopanib, a new therapy for metastatic soft tissue sarcoma
AbstractINTRODUCTION: Pazopanib (GW786034, Votrient®) is a vascular endothelial growth factor receptor-focused multi-tyrosine kinase inhibitor involved in inhibiting the angiogenesis pathway. The agent was recently registered for use in soft tissue sarcomas, a group of diseases with a major unmet medical need. AREAS COVERED: The relevance of angiogenesis in soft tissue sarcomas is discussed. These data were the basis to decide on the development of pazopanib in these diseases. The clinical pharmacology of pazopanib, as far as practically relevant, is summarized. After the first observations of possible activity in soft tissue sarcomas in the Phase I study, a Phase II and subsequent randomized placebo-controlled Phase III study were performed and are being put into perspective in this review. EXPERT OPINION: Pazopanib is an active drug for the treatment of chemotherapy-failing nonadipocytic soft tissue sarcomas. It almost triples progression-free survival significantly from 1.6 to 4.6 months in this heavily pretreated population. The safety profile is manageable, exemplified by the high dose intensity that can be achieved over time. Pazopanib can be considered as part of the standard of care for patients with soft tissue sarcomas.
American Journal of Health-System Pharmacy · 2006 · 24 citations
Cancer-treatment-induced bone loss, part 2
AbstractPURPOSE: The pathophysiology, frequency, sequelae, diagnosis, and treatment of cancer-treatment-induced bone loss (CTIBL) are discussed. SUMMARY: CTIBL is a long-term complication associated with cancer therapies that can directly or indirectly affect bone metabolism. Although CTIBL can occur in any patient receiving a cancer therapy known to cause bone loss, CTIBL is most common in patients with breast or prostate cancer who receive chemotherapy, hormone therapy, or surgical castration, as these can cause hypogonadism and induce bone loss. CTIBL causes bone fragility and an increased susceptibility to fractures; therefore, prevention, early diagnosis, and treatment of CTIBL are essential to decrease the risk of fracture. Bone loss occurs more rapidly and tends to be more severe in patients with CTIBL compared with those with normal age-related bone loss. Fractures of the hip, vertebra, and wrist are the fractures most commonly associated with bone loss. CTIBL is diagnosed by measuring bone mass using bone densitometry. Treatment of CTIBL consists of changing diet and lifestyle such as optimizing calcium and vitamin D intake, exercising, modifying behaviors known to increase the risk of CTIBL and pharmacologic therapy with hormone replacement therapy (HRT), selective estrogen-receptor modifiers (SERMs), calcitonin, or a bisphosphonate. CONCLUSION: Early identification and treatment of CTIBL are essential to prevent fractures. Patients should be instructed to optimize calcium and vitamin D intake, exercise regularly, and modify lifestyle behaviors known to cause bone loss. Patients with CTIBL should be treated with an oral or i.v. bisphosphonate; SERMs or HRT may be an option in some patients if contraindications do not exist.
Journal of Materials Chemistry B · 2016 · 11 citations
Self-assembly of dual drug-delivery coating for synergistic bone regeneration
AbstractBone regeneration for the treatment of bone diseases represents a major clinical need. Introducing recombinant human bone morphogenetic protein-2 (rhBMP-2) into biomaterials is an extensively used approach to induce osteogenic differentiation and accelerate bone regeneration. However, serious adverse events can occur in the event of an overdose of rhBMP-2. Dexamethasone (DEX) is a synthetic hydrophobic glucocorticoid, which can enhance rhBMP-2-induced osteogenic differentiation by binding to a glucocorticoid receptor intracellularly. In this study, we have developed a multilayered composite coating made of poly(l-lactide-co-glycolide) (PLGA) nanoparticles, heparin and chitosan to deliver DEX and rhBMP-2 dually. The coating can reserve DEX and rhBMP-2 using the building blocks of the PLGA nanoparticles and heparin. Sustained release of DEX and rhBMP-2 by this coating was achieved. Moreover, a flow cytometry assay suggests that the PLGA nanoparticles could be transported across the cell membrane and presumably could improve the intracellular delivery of DEX via cell internalization. The in vitro osteogenesis studies reveal that the dual drug-loaded coating has a synergistic osteogenic differentiation effect on C2C12 myoblasts, as indicated by the upregulation of the alkaline phosphatise activity and osteo-related gene expression. In addition, μCT and histological analysis of the in vivo experiments demonstrate that the dual drug-loaded coating induced more ectopic bone formation than the individual drug-loaded coating. Therefore, this study demonstrates that our coating system can reserve these two drugs and deliver them locally to cells with the ability to induce rapid osteogenic differentiation and bone regeneration synergistically. Compared to other reported DEX/rhBMP-2 delivery systems, our coating system represents a simple, safe and effective dual drug delivery alternative. Moreover, since a layer-by-layer strategy is easily applied onto varying substrates, our coating system can be combined with many commercially available or existing biomaterials to improve their osteogenetic performance.
Bone Disease - Current Knowledge and Future Prospects
AbstractThe advent of genomics approaches to studying human disease have yielded a large number of genes and gene families that are involved in the process of bone formation and bone remodeling. The identification and characterization of these genes has provided significant insights into the pathogenesis of numerous human bone diseases. This review details current understanding of the role of many of these genes in bone development and disease. We review the current status of bone disease prevention/treatment modalities and describe how recent advances in our understanding of the molecules responsible for different aspects of osteoblast, osteoclast and chondrocyte function may provide novel biochemical markers and treatment strategies for bone disease. Keywords: Bone Disease, Aromatase Deficieny, linked dominant Conradi-Hunermann, Down Syndrome skeletal abnormalities, Ellis-van Creveld syndrome, Crouzon syndrome, Apert syndrome, Pfeiffer syndrome, multiple epiphyseal dysplasia (MED), achondroplasia
Annals of the New York Academy of Sciences · 2025 · 1 citations
Mesenchymal Stem Cell Transplantation for Osteogenesis Imperfecta Patients: A Systematic Review
AbstractThe following systematic review provides an evaluation of the effectiveness of mesenchymal stem cell (MSC) transplantation in the treatment of osteogenesis imperfecta (OI). After reviewing 40 studies, 9 human clinical studies that included case reports or case series were included and resulted in a total of 12 patients with OI. Five studies documented an increase in total body bone mineral (TBBM) content, whereas four studies observed a reduction in fracture rates post-transplantation. Moreover, noticeable improvements in children's growth were recorded. Although both BMSCs and human fetal MSCs (hfMSCs) were found to be effective, studies involving BMSCs were rated higher in terms of methodological quality. Both BMSCs and hfMSCs demonstrated significant improvements in TBBM, growth rates, and fracture reduction, with BMSC studies scoring higher in methodological quality. Future randomized clinical trials with longer follow-ups are necessary.
Palliative Radiotherapy for Large Osteolytic Metastatic Tumors Involving the Iliac Bone: A Report of 16 Cases
AbstractBACKGROUND/AIM: Among the bones that compose the pelvis, the ilium is the most commonly affected by metastatic tumors. The objective of our study was to describe the outcomes after palliative radiotherapy (PRT) of osteolytic metastatic tumors involving the iliac bone (OMTIB). PATIENTS AND METHODS: Sixteen symptomatic patients with OMTIB were treated with PRT during a six-year period. The mean maximum diameter of the pelvic bone lesions was 9.3 cm (range=3.4-16 cm). OMTIB affected the iliac bone alone (six patients), the adjacent pelvic bones or muscles (seven patients), or both structures (three patients). The irradiation dose-fractionation scheme was ≥30 Gy given in 10 to 15 fractions. RESULTS: Pain response rates were: good in 44% (7/16) of cases, fair in 25% (4/16), and poor in 31% (5/16). After treatment, mobility outcomes exhibited ambulation in 69% (9/13) and non-ambulation in 31% (4/13). During follow-up, the effects of PRT on OMTIB were reflected as stability in 28% (3/11), enlargement in 36% (4/11), and re-calcification in 36% (4/11). The overall survival rates at one and two years were 44% (7/16) and 19% (3/16), respectively; median survival was two months. CONCLUSION: Although the prognosis of OMTIB is poor, PRT is an effective treatment for pain relief, improving mobility and promotion of bone repair.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
